ClinicalTrials.gg
CompletedNCT03491462Updated Aug 24, 2023Results posted

Arimoclomol in Amyotropic Lateral Sclerosis

A Phase 3 interventional study of Arimoclomol and Placebo in Amyotrophic Lateral Sclerosis, sponsored by ZevraDenmark. Completed at 29 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-24.

Sponsored by ZevraDenmark · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Enrollment
35th of 307
245 · median 33
Started
2018
with 19 others
Phase 3
30 of 440
3 open now
Registered
213th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 35th largest by enrollment of the 307 interventional ones that give a count, is one of 20 that started in 2018, is one of 30 in phase 3, and was the 213th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

A multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of arimoclomol in amyotropic lateral sclerosis (ALS)

Read the detailed description

Screening up to 4 weeks Treatment up to 76 weeks

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • Arimoclomol
  • ALS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject meets revised El Escorial criteria for clinically possible, clinically probable / clinically probable ALS laboratory-supported, clinically definite ALS or clinically definite familial ALS laboratory-supported
  • 18 months or less since first appearance of weakness (e.g. limb weakness, dysarthria, dysphagia, shortness of breath)
  • ALS Functional Rating Scale-Revised (ALSFRS-R) equal to or above 35 and erect (seated) Slow Vital Capacity (SVC) % predicted equal to or above 70% at Screening

Exclusion criteria

Exclusion Criteria:

  • Tracheostomy or use of non-invasive ventilation for more than 2 hours during waking hours at the time of Screening and Baseline
  • Pregnant or breast-feeding
  • Current or anticipated use of diaphragmatic pacing
  • Any other relevant medically significant condition which could present risk to the subject or interfere with the assessment of safety or has an increased risk of causing death during the trial
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
245 participants (actual)

Study arms

  • Experimental
    Arimoclomol

    248 mg arimoclomol base (equivalent to 400 mg arimoclomol citrate) 3 times daily

    Drug: Arimoclomol

  • Placebo comparator
    Placebo

    248 mg matching placebo 3 times daily

    Drug: Placebo

Interventions

  • 2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily

  • DrugPlacebo

    2 matched placebo capsules taken 3 times daily

06

What researchers measure

Primary outcomes

  1. Combined Assessment of Function and Survival (CAFS)

    Combined Assessment of Function and Survival (CAFS) is a composite endpoint that includes 1) the change from baseline in revised ALS functional rating scale (ALSFRS-R) and 2) the survival endpoint (time to permanent assisted ventilation \[PAV\], tracheostomy or death). On the ALSFRS-R, 12 functions are rated on 5-point ordinal rating scales (from 0 to 4) with a total score range (minimum and maximum score) of 0-48 (sum of all 12 items). The higher the score the better functioning. For the survival endpoint, the longer time to PAV, tracheostomy, or death the better outcome. A patient's CAFS score represents a patient's rank in the study based on comparing the patient's outcome for both the change in ALSFRS-R and the time to event (PAV, tracheostomy, or death) to the outcome for all other patients in the study in a pairwise fashion. A higher rank score (range 0-1) is considered a better outcome. The reported values are the mean rank scores in each group for the composite endpoint.

    Time frame: Over 76 Weeks

Secondary outcomes

  1. Time to Permanent Assisted Ventilation (PAV) / Tracheostomy / Death

    Time from baseline to one of the events (PAV / tracheostomy / death). PAV is defined as the first of 7 consecutive days on which PAV was used for \>22 hours/day

    Time frame: Over 76 weeks

  2. Change From Baseline to Week 76 (or End-of-trial) in the Revised ALS Functional Rating Scale (ALSFRS-R)

    The ALSFRS-R score is based on a rating scale where 12 functions are rated on 5-point ordinal rating scales (from 0 to 4) with a maximum score of 48 (sum of all 12 items). The higher the score the better functioning.

    Time frame: Week 76 (or end of trial)

  3. Change From Baseline to Week 76 (or End-of-trial) in Percent (%) Predicted Slow Vital Capacity (SVC)

    Slow Vital Capacity (SVC) is a measure of breathing function. SVC measures the volume that can be exhaled from a full inhalation after exhaling to a maximum as slowly as possible. The percent (%) of predicted SVC is reported.

    Time frame: Week 76 (or end of trial)

07

Results

Posted Aug 24, 2023

Participant flow

Participant flow — Overall Study
MilestoneArimoclomol (up to 76 Weeks)Placebo (up to 76 Weeks)
Started16079
Completed12263
Not completed3816
Withdrew: Lost to follow-up20
Withdrew: Adverse event111
Withdrew: Physician decision30
Withdrew: Withdrawal by subject2215

Outcome measures

PrimaryCombined Assessment of Function and Survival (CAFS)

Combined Assessment of Function and Survival (CAFS) is a composite endpoint that includes 1) the change from baseline in revised ALS functional rating scale (ALSFRS-R) and 2) the survival endpoint (time to permanent assisted ventilation \[PAV\], tracheostomy or death). On the ALSFRS-R, 12 functions are rated on 5-point ordinal rating scales (from 0 to 4) with a total score range (minimum and maximum score) of 0-48 (sum of all 12 items). The higher the score the better functioning. For the survival endpoint, the longer time to PAV, tracheostomy, or death the better outcome. A patient's CAFS score represents a patient's rank in the study based on comparing the patient's outcome for both the change in ALSFRS-R and the time to event (PAV, tracheostomy, or death) to the outcome for all other patients in the study in a pairwise fashion. A higher rank score (range 0-1) is considered a better outcome. The reported values are the mean rank scores in each group for the composite endpoint.

Time frame:
Over 76 Weeks
Reported as:
Mean · score on a scale
Combined Assessment of Function and Survival (CAFS)
score on a scaleArimoclomol (up to 76 Weeks)Placebo (up to 76 Weeks)
Combined Assessment of Function and Survival (CAFS)0.51 ± 0.2910.49 ± 0.283
Statistical analysis
  • Arimoclomol (up to 76 Weeks) vs Placebo (up to 76 Weeks) · Gehan's extended Wilcoxon's test · p = 0.6208
SecondaryTime to Permanent Assisted Ventilation (PAV) / Tracheostomy / Death

Time from baseline to one of the events (PAV / tracheostomy / death). PAV is defined as the first of 7 consecutive days on which PAV was used for \>22 hours/day

Time frame:
Over 76 weeks
Reported as:
Median · days
Time to Permanent Assisted Ventilation (PAV) / Tracheostomy / Death
daysArimoclomol (up to 76 Weeks)Placebo (up to 76 Weeks)
Time to Permanent Assisted Ventilation (PAV) / Tracheostomy / DeathNA (479 to NA)NA (466 to NA)
SecondaryChange From Baseline to Week 76 (or End-of-trial) in the Revised ALS Functional Rating Scale (ALSFRS-R)

The ALSFRS-R score is based on a rating scale where 12 functions are rated on 5-point ordinal rating scales (from 0 to 4) with a maximum score of 48 (sum of all 12 items). The higher the score the better functioning.

Time frame:
Week 76 (or end of trial)
Reported as:
Mean · units on a scale
Change From Baseline to Week 76 (or End-of-trial) in the Revised ALS Functional Rating Scale (ALSFRS-R)
units on a scaleArimoclomol (up to 76 Weeks)Placebo (up to 76 Weeks)
Change From Baseline to Week 76 (or End-of-trial) in the Revised ALS Functional Rating Scale (ALSFRS-R)-15.4 ± 8.71-15.0 ± 9.10
SecondaryChange From Baseline to Week 76 (or End-of-trial) in Percent (%) Predicted Slow Vital Capacity (SVC)

Slow Vital Capacity (SVC) is a measure of breathing function. SVC measures the volume that can be exhaled from a full inhalation after exhaling to a maximum as slowly as possible. The percent (%) of predicted SVC is reported.

Time frame:
Week 76 (or end of trial)
Reported as:
Mean · percent (%) predicted SVC
Change From Baseline to Week 76 (or End-of-trial) in Percent (%) Predicted Slow Vital Capacity (SVC)
percent (%) predicted SVCArimoclomol (up to 76 Weeks)Placebo (up to 76 Weeks)
Change From Baseline to Week 76 (or End-of-trial) in Percent (%) Predicted Slow Vital Capacity (SVC)-30.65 ± 26.346-30.38 ± 23.839

Adverse events

Collected over From first dose of study medication up to 76 weeks. Assessed every week.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arimoclomol (up to 76 Weeks)29/160 (18.1%)36/160 (22.5%)149/160 (93.1%)
Placebo (up to 76 Weeks)18/79 (22.8%)20/79 (25.3%)71/79 (89.9%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventArimoclomol (up to 76 Weeks)Placebo (up to 76 Weeks)
PneumoniaInfections and infestations4/1605/79
Pulmonary embolismRespiratory, thoracic and mediastinal disorders7/1602/79
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders2/1602/79
Respiratory failureRespiratory, thoracic and mediastinal disorders2/1602/79
Femur fractureInjury, poisoning and procedural complications0/1602/79
Deep vein thrombosisVascular disorders3/1600/79
StridorRespiratory, thoracic and mediastinal disorders0/1601/79
BronchitisInfections and infestations0/1601/79
DiverticulitisInfections and infestations0/1601/79
InfluenzaInfections and infestations0/1601/79
Most frequent other events
Showing 10 of 31
Most frequent other events
EventArimoclomol (up to 76 Weeks)Placebo (up to 76 Weeks)
HeadacheNervous system disorders34/16021/79
FallInjury, poisoning and procedural complications33/16017/79
ConstipationGastrointestinal disorders32/16010/79
NasopharyngitisInfections and infestations14/16015/79
NauseaGastrointestinal disorders27/1603/79
InsomniaPsychiatric disorders23/1607/79
DiarrhoeaGastrointestinal disorders16/1608/79
DizzinessNervous system disorders16/1604/79
Oedema peripheralGeneral disorders15/1605/79
Back painMusculoskeletal and connective tissue disorders14/1607/79

Baseline characteristics

All participants in the modified intention-to-treat (mITT) population

Age, Continuous
Age, Continuous(years)Arimoclomol (up to 76 Weeks)Placebo (up to 76 Weeks)Total
Mean58.0 ± 11.2656.6 ± 9.9757.6 ± 10.85
Sex: Female, Male
Sex: Female, Male(Participants)Arimoclomol (up to 76 Weeks)Placebo (up to 76 Weeks)Total
Female543488
Male10645151
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arimoclomol (up to 76 Weeks)Placebo (up to 76 Weeks)Total
Hispanic or Latino13720
Not Hispanic or Latino13264196
Unknown or Not Reported15823
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arimoclomol (up to 76 Weeks)Placebo (up to 76 Weeks)Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American112
White13666202
More than one race000
Unknown or Not Reported231134
Revised ALS Functional Rating Scale (ALSFRS-R)
Revised ALS Functional Rating Scale (ALSFRS-R)(units on a scale)Arimoclomol (up to 76 Weeks)Placebo (up to 76 Weeks)Total
Mean40.6 ± 3.9340.2 ± 3.6540.5 ± 3.83
Percent (%) Predicted Slow Vital Capacity (SVC)
Percent (%) Predicted Slow Vital Capacity (SVC)(percent (%) predicted SVC)Arimoclomol (up to 76 Weeks)Placebo (up to 76 Weeks)Total
Mean95.8 ± 15.9898.1 ± 14.7896.5 ± 15.60
08

Study locations

29 sites
  • St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center
    Phoenix, Arizona 85013, United States
  • HonorHealth Neurology
    Phoenix, Arizona 85018, United States
  • UC Irvine Health ALS and Neuromuscular Center
    Orange, California 92868, United States
  • University of Miami
    Miami, Florida 33136, United States
  • University of Kansas Medical Center (KUMC) - Landon Center on Aging
    Kansas City, Kansas 66160, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • Providence Brain & Spine Institute
    Portland, Oregon 97213, United States
  • University of Pensylvania, Perelman Center for Advanced Medicine - Penn Neuroscience Center
    Philadelphia, Pennsylvania 19107, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Catholic University Leuven
    Leuven, 3000, Belgium
  • London Health Sciences Centre
    London, Ontario N6A 5A5, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • Montreal Neurological Institute and Hospital
    Montréal, Quebec H3A 2B4, Canada
  • Centre Hospitalier Regional Universitaire (CHRU) Montpellier - Hopital Gui De Chauliac
    Montpellier, 34295, France
  • Groupe Hospitalier Pitie-Salpetriere - Centre d'Investigation Clinique Neurosciences 1422
    Paris, 75013, France
  • Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK) - Ambulanz fuer ALS und andere Motoneuronenerkrankungen
    Berlin, 13353, Germany
  • Medizinische Hochschule Hannover (MHH) - Klinik fuer Neurologie
    Hannover, 30625, Germany
  • Universitaetsklinikum Ulm - Klinik fuer Neurologie
    Ulm, 89081, Germany
  • Instituti Clinica Scientifici Maugeri - IRCCS
    Milano, 20138, Italy
  • Azienda Ospedaliero Universitaria (AUO) di Torino - Citta'della Salute e della Scienza di Torino
    Torino, 10126, Italy
  • University Medical Center Utrecht
    Utrecht, 3584CX, Netherlands
  • Centrum Medyczne NeuroProtect
    Warsaw, 01-684, Poland
  • Citi Clinic
    Warsaw, 02-473, Poland
  • Hospital Universitario Vall d'Hebron ALS Unit. Consultas Externas; Office: 9-10-11
    Barcelona, 08035, Spain
  • Hospital Carlos III - Hospital Universitario La Paz, ALS Unit
    Madrid, 28046, Spain
  • Umeå University Hospital
    Umeå, 90737, Sweden
  • Kantonsspital St.Gallen, Muskelzentrum/ALS Clinic
    Saint Gallen, 9007, Switzerland
  • Leonard Wolfson Experimental Neurology Centre
    London, WC1N 3BG, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Dec 2020, 28 months.

Results were first posted in Aug 2023, 2 years 8 months after primary completion.

Of 24 phase 3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 28 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2018
First posted
Apr 9, 2018
StartActual
Jul 31, 2018
Primary completionActual
Dec 18, 2020
CompletionActual
Dec 18, 2020
Results first posted
Aug 24, 2023
Last update
Aug 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03491462
Lead sponsor
ZevraDenmark
Responsible party
Sponsor
First posted
Apr 9, 2018
Start date
Jul 31, 2018
Primary completion
Dec 18, 2020
Completion
Dec 18, 2020
Results posted
Aug 24, 2023
Last update
Aug 24, 2023

Study contacts

Michael Benatar, MD PhD
principal investigator · University of Miami

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arimoclomol

Start the discussion